Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.820
-0.030 (-1.05%)
Apr 22, 2026, 10:48 AM EDT - Market open
Ovid Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Ovid Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.60, which forecasts a 63.12% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $7.00.
Price Target: $4.60 (+63.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ovid Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $7 | Buy | Reiterates | $7 | +148.23% | Apr 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $2 → $4 | Strong Buy | Maintains | $2 → $4 | +41.84% | Apr 9, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +41.84% | Mar 26, 2026 |
| Wedbush | Wedbush | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +148.23% | Mar 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2 | Strong Buy | Reiterates | $2 | -29.08% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
230.78K
from 7.25M
Decreased by -96.82%
Revenue Next Year
275.40K
from 230.78K
Increased by 19.34%
EPS This Year
-0.53
from -0.23
EPS Next Year
-0.64
from -0.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.2M | 1.2M | ||||||
| Avg | 230,775 | 275,400 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -83.9% | 405.3% | ||||||
| Avg | -96.8% | 19.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.36 | -0.40 | |||
| Avg | -0.53 | -0.64 | |||
| Low | -1.02 | -1.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.